Spero Therapeutics (SPRO) said late Tuesday it will suspend its development program for SPR720 as a potential treatment for nontuberculous mycobacterial pulmonary disease after a phase 2a trial failed to achieve its primary endpoint.
Data from the trial did not show sufficient separation from placebo, while highlighting potential safety issues in some subjects, the company said.
As a result of the suspension, the company plans to cut its workforce by about 39% and restructure its operations in order to extend the company's cash runway into mid-2026.
Shares of Spero Therapeutics were down nearly 24% in premarket activity Wednesday.
Price: 1.0000, Change: -0.31, Percent Change: -23.66
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。